10 pending office actions • 3 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Gilead Sciences, Inc. | 5 |
| Cymabay Therapeutics, Inc. | 3 |
| Forty Seven, LLC | 2 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18696850 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | Gilead Sciences, Inc. | WILLIS, DOUGLAS M | 1624 | Non-Final OA | Mar 28, 2024 |
| 18423232 | Treatment of chronic pruritic dermatoses | Cymabay Therapeutics, Inc. | MARTIN, KEVIN STEPHEN | 1624 | Non-Final OA | Jan 25, 2024 |
| 18373655 | ANTI-CD47 AGENT-BASED OVARIAN CANCER THERAPY | Forty Seven, LLC | DENT, ALANA HARRIS | 1643 | Non-Final OA | Sep 27, 2023 |
| 18264670 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. | AULAKH, CHARANJIT | 1621 | Non-Final OA | Aug 08, 2023 |
| 18268469 | 6-SUBSTITUTED INDOLE COMPOUNDS | Gilead Sciences, Inc. | RAO, PADMAJA S | 1627 | Non-Final OA | Jun 20, 2023 |
| 18268440 | SUBSTITUTED INDOLE COMPOUNDS | Gilead Sciences, Inc. | REILLY, SOPHIA JANE | 1627 | Final Rejection | Jun 20, 2023 |
| 18180438 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. | LEESER, ERICH A | 1622 | Non-Final OA | Mar 08, 2023 |
| 17916994 | ANTIBODY FORMULATION | Forty Seven, LLC | HADDAD, MAHER M | 1641 | Final Rejection | Oct 04, 2022 |
| 17588273 | Treatment of cholangiopathies | Cymabay Therapeutics, Inc. | SCHMITT, MICHAEL J | 1629 | Final Rejection | Jan 29, 2022 |
| 17128195 | Treatment of cholestatic pruritus | Cymabay Therapeutics, Inc. | CORNET, JEAN P | 1628 | Final Rejection | Dec 21, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial